Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hospital hep c treatment aims to cure drug users

NCT ID NCT03981211

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested giving hepatitis C treatment to people who inject drugs while they were already in the hospital for other infections. The goal was to cure their hepatitis C and make sure they stayed connected to care afterward. The study was stopped early, but it included 21 participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Started

Feb 2021

Finished

Sep 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all of the following inclusion criteria to be eligible to participate in this study. 1. Have voluntarily signed the informed consent form. 2. 18 years of age or older. 3. Injected drugs within the last 6 months 4. Hospitalised with an IRID with an anticipated inpatient stay of \> 1 week Participants must meet the following additional inclusion criteria to be treated in this study. 5. HCV RNA positive 6. Compensated liver disease 7. Documented non-cirrhotic at enrolment with a qualifying liver FibroScan ≤ 9.5 kpA 8. If co-infection with HIV is documented, the subject must meet the following criteria: 1. ART naïve with CD4 T cell count \>500 cells/mm3; OR 2. On a stable ART regimen (containing only permissible ART) for \>4 weeks prior to screening visit, with CD4 T cell count ≥200 cells/mm3 and a plasma HIV RNA level below the limit of detection. Exclusion Criteria: Participants who meet any of the exclusion criteria are not to be enrolled in this study. 1. Inability or unwillingness to provide informed consent or abide by the requirements of the study 2. Actively intoxicated. Participants that meet any of the additional exclusion criteria are not to be treated in this study. 3. History of any of the following: b. Clinical hepatic compensation (i.e. ascites, encephalopathy or variceal haemorrhage) c. Solid organ transplant d. History of severe, life-threatening or other significant sensitivity to study drugs (glecaprevir/pibrentasvir/sofosbuvir) or any excipients of the study drugs 4. Creatinine clearance (CLcr) \< 30 mL/min at screening (Cohort B only) 5. Pregnant or nursing female 6. Decompensated liver disease 7. Use of prohibited concomitant medications 8. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone equivalent \> 10 mg/day for \>2 weeks) 9. Prior treatment failure with an NS5A based DAA regimen Patients without an IRID but who fulfill all other criteria and are admitted with an expected duration of stay \> 1 week may also be included at discretion of study team.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Blacktown Mt Druitt Hospital

    Sydney, New South Wales, 2148, Australia

  • Prince of Wales Hospital

    Randwick, New South Wales, 2031, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • St Vincent's Hospital

    Melbourne, Victoria, 3065, Australia

  • St Vincent's Hospital Sydney

    Sydney, New South Wales, 2010, Australia

  • The Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.